Double-Blind, Placebo-Controlled Dose-Finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy.

Trial Profile

Double-Blind, Placebo-Controlled Dose-Finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs CMP 001 (Primary)
  • Indications Allergic rhinoconjunctivitis; Hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 31 Jul 2009 Primary endpoint 'Symptom score' (Rhinoconjunctivitis symptom and medication scores) has been met according to a Cytos Biotechnology media release. Secondary endpoints have also been met.
    • 31 Jul 2009 Results will be presented at an upcoming meeting according to a Cytos Biotechnology media release. Results were also reported in the media release.
    • 28 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top